Key result
Dextran-70 strongly inhibits PAF-induced aggregation in equine platelets.
Why the study?
Does dextran-70 inhibit agonist-induced platelet aggregation in equine platelet suspensions?
Population
Equine platelet suspensions (in vitro model)
Comparison
Dextran-70 (concentrations up to 60 g/l) vs Control and other agonists
Design
Preclinical
Authors
Loading...
May warrant equine antithrombotic trials; leaves open translation of PAF inhibition to clinical colic outcomes.
Does dextran-70 inhibit agonist-induced platelet aggregation in equine platelet suspensions?
p-value: p=<0.001
Dextran-70 specifically inhibits PAF-induced aggregation in equine platelets, providing a potential mechanism for its anti-thrombotic efficacy in treating equine thromboembolic colic.
Heath et al. (1998) studied Equine platelet suspensions (in vitro). Dextran-70 was evaluated on Platelet-activating factor (PAF)-induced aggregation (p=<0.001). Dextran-70 (60 g/l) significantly inhibited the rate and extent of platelet-activating factor (PAF)-induced aggregation in equine platelets (P<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: